Objective: To determine the effects of chlorhexidine gluconate (CHG) on skin inflammation and stratum corneum barrier integrity at peripherally inserted central catheter (PICC) sites among patients in the neonatal intensive care setting.
Introduction
The incidence of nosocomial infection among neonatal intensive care patients ranges from 7 to 24.5%, with central venous catheterassociated blood stream infections being the most common type. [1] [2] [3] Catheter hub and exit-site colonization, birth weight <1000 g at insertion, time on parenteral nutrition and insertion after day 7 were independently related to blood stream infections. 2 The Centers for Disease Control guideline recommends skin disinfection with 2% chlorhexidine gluconate (CHG, preferred), tincture of iodine, an iodophor or 70% alcohol for adults and older pediatric patients, but states that no recommendation can be made for infants <2 months because of limited evidence or lack of consensus. 4, 5 Our institution (Cincinnati Children's Hospital Medical Center) implemented the use of CHG in place of povidone-iodine in the neonatal intensive care unit (NICU) (Regional Center for Newborn Intensive Care) in 2004 and found a significant reduction in blood stream infections from 3.6 to 0.7 per 1 000 catheter days.
The literature on the skin effects of CHG in neonates is very limited. The premature infant has a poor epidermal barrier with few cornified layers and is at risk for increased permeability to exogenous materials, additional skin compromise, delayed barrier maturation and infection. 6, 7 The dermis is deficient in structural proteins and the skin is easily torn. 8 Alcohol-based preparations, including CHG in 70% isopropanol, have been reported to cause burns in infants of 24 to 26 weeks gestational age (GA). 9, 10 The skin effects of CHG were examined in parallel groups of 715 NICU patients with central venous catheters. The sites were treated with isopropanol and covered with either a polyurethane dressing (Bioclusive Transparent Dressing (Bioclusive, Johnson & Johnson, New Brunswick, NJ, USA)) or a chlorhexidine antiseptic dressing (Biopatch Antimicrobial Dressing, Johnson & Johnson, New Brunswick, NJ, USA). 11 Severe contact dermatitis was noted in 5.7% of CHG patch subjects of 22.5 to 26.5 weeks GA. The effects of the patch itself could not be determined. CHG (0.05%) in water was significantly more irritating than povidone iodine and no treatment in vitro.
12 CHG (4%) in water and CHG (0.5%) in 70% ethanol were less irritating than iodine and hypochlorite in repeated open patch tests on the undamaged adult forearm skin. 13 We examined the effects of CHG on skin irritation and stratum corneum (SC) barrier integrity through the hypothesis that CHG would not alter barrier development. We investigated the effects of CHG (Chloraprep (Enturia, Leawood, KS, USA), 2% CHG, 70% alcohol, water) on the skin at peripherally inserted central catheter (PICC) sites among NICU patients. Using a within-subject design, PICC sites treated with CHG plus a semipermeable (Tegaderm, 3M, St Paul, MN, USA) dressing were compared with a contralateral dressing site (Tegaderm) and an adjacent untreated control.
Methods

Subjects
Infants were recruited from January to October of 2007. The research was approved by the Institutional Review Board. Parents/guardians provided written informed consent. Exclusions were GA X40 weeks, PICC location other than an arm or leg, expected duration for PICC of <14 days, congenital epidermal defects, medically unable to tolerate measurements and the use of phototherapy. GA was confirmed by examination upon admission. Skin evaluations occurred before insertion when possible and at weekly dressing changes. Prophylactic antibiotics were not given. However, subjects received antibiotics as required for their medical condition.
Outcomes
The primary outcome was skin condition, measured as irritation (erythema and dryness/scaling) and SC barrier integrity (transepidermal water loss, TEWL in g m -2 h
À1
). A secondary outcome was the immediate irritant response to CHG application measured as visual skin erythema. Infection rates were monitored per policy. On the basis of the anticipated TEWL differences and standard deviations, a sample size of 45 to 50 infants was required to determine the effects of CHG.
Procedures
Each skin site was evaluated for visual erythema and dryness using standardized scales (erythema 7-point 0 to 3, 0.5 grade increments; dryness 11-point, 0 to 5, 0.5 grade increments) based on site area of involvement and intensity of the compromise (Appendix Tables,  A, B). 14,15 TEWL (g m -2 h À1 ) of B120 mm 2 area was measured with a closed chamber device (VapoMeter, Delfin Technologies, Ltd, Kuopio, Finland) using standardized protocols. 16 The location of PICC insertion (arm, leg, left versus right) was not randomly assigned but was on the basis of the availability of a suitable insertion site. The contralateral site was treated with dressing alone. An area adjacent to the PICC site (for example, the upper arm for arm PICCs) was the untreated control. Research personnel were unaware of the time of exposure to CHG (ChloraPrep) and dressing (Tegaderm). Six PICC-certified nurses and the investigator (Visscher) conducted the evaluations. The PICC site was 2.5 cm Â 2.5 cm around the catheter. After insertion, a transparent semipermeable (semi-occlusive) adhesive dressing (Tegaderm) was affixed to the skin and the line secured with steri strips. As per the hospital policy, dressings were changed weekly using saline to facilitate removal and the site was allowed to dry for 5 min. Immediate erythema was assessed 2 min after CHG application, once redness due to friction had dissipated, and a new dressing applied. Tegaderm (2.5 Â 2.5 cm) was applied to the contralateral site, removed and reapplied weekly. Measurements were made before insertion whenever possible and at weeks 1, 2 and 3. Subjects were retained in the data set if they were evaluated at least twice.
Statistical analysis
Treatment comparisons of erythema, dryness and TEWL were made using analysis of variance (ANOVA) (Pp0.05) and appropriate pairwise comparisons (SigmaStat, SPSS Inc., Chicago, IL, USA) at insertion and at dressing changes at weeks 1, 2 and 3. The withinsubject design insured that all the number of subjects was the same for the three treatments at each time point. Paired t-tests of erythema before and 2 min after CHG application were used to determine the immediate response (P p0.05). In addition, treatment effects were assessed for over the 3-week time frame using linear mixed models repeated measures procedures (covariance-type diagonal, F-statistics, P p0.05) (SPSS, SPSS). This permits analysis of subjects measured at different times during treatment in which the effects at any given time are influenced by previous treatments. The specific repeated measures method allows for the missing data by computing estimated values. GA and age at start were included as covariates to insure that treatment effects were not biased by these factors. Treatments were compared with the method of Bonferroni.
Results
Forty infants with respiratory, gastrointestinal, genetic, cardiac, congenital or neurological conditions met the inclusion criteria and were evaluated at two or more time points. The mean GA was Abbreviation: PICC, peripherally inserted central catheter.
Chlorhexidine and skin integrity M Visscher et al 32.1 ± 4.7 weeks (Table 1 ). An additional 20 subjects were enrolled but could not continue into the measurement phase because of the placement of PICC in other locations or the removal of PICC within 1 week. Fourteen subjects had PICCs in place at the week-3 evaluation time. The enrollment rate was about 80% of those eligible. There were no catheter-associated infections and no increase in catheter-associated infection rates compared with historical data since CHG implementation. Two infants died from complications unrelated to the study. Skin erythema at baseline differed for the three sites (ANOVA, P ¼ 0.02), but post hoc pairwise comparisons were not significant ( Figure 1 ). The sites were comparable for baseline dryness and TEWL (ANOVA, P<0.05) (Figures 2 and 3) . Starting PICC-site erythema was inversely correlated with age at start (correlation coefficient, r ¼ À0.66, P ¼ 0.000) and modestly with GA (r ¼ À0.44, P ¼ 0.02). Baseline TEWL values (dressing, control) were inversely related to age at start (r ¼ 0.71, P ¼ 0.000 dressing; r ¼ À0.47, P ¼ 0.01 control) and modestly correlated with GA (r ¼ À0.40, P ¼ 0.05, dressing). At week 1, the sites differed for erythema (ANOVA, P<0.001) with the highest score (indicating poorest skin condition) for the PICC site (Figure 1) . By week 3, erythema scores were comparable for the PICC and dressing sites and both were higher than the control (ANOVA, P ¼ 0.000). Skin dryness was observed at study start. At week 1, the PICC site was drier than the dressing and control sites (ANOVA, P<0.001) (Figure 2) . By week 3, dryness was comparable for the PICC and dressing sites and higher than the control. At week 1, PICC-site TEWL was higher than the control, indicating SC barrier compromise ( Figure 3 ) and by week 3 it was higher than dressing and control (ANOVA, P ¼ 0.002). Analysis by linear mixed models with repeated measures over 3 weeks confirmed the findings for erythema (F ¼ 70.1, P ¼ 0.000), dryness (F ¼ 17.9, P ¼ 0.000) and TEWL (F ¼ 11.2, P ¼ 0.000) (data not shown). Time from birth (age at start minus GA) was a covariate for dryness and TEWL. Erythema immediately after CHG application was directionally increased at PICC insertion (P ¼ 0.09) and directionally decreased at week 1 (P ¼ 0.07) ( Table 2) . Scores were not different at weeks 2 and 3. Figure 3 Stratum corneum barrier integrity (TEWL, transepidermal water loss). After 1 week, TEWL was higher than the control, indicating a compromised stratum corneum barrier. By week 3, peripherally inserted central catheter (PICC)-site TEWL was higher than the dressing and untreated sites. *Different week 1, P<0.001. # PICC differs from dressing and control, P ¼ 0.002. Abbreviations: CHG, chlorhexidine gluconate; PICC, peripherally inserted central catheter.
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The skin effects of CHG are of particular interest for very premature infants, that is, p29 weeks GA. Although our sample size in this age range was very limited (n ¼ 14), we conducted a secondary analysis among this subset. The findings were similar to those for the entire group (data not shown). Erythema differed for all sites at week 1 (ANOVA, P<0.05). At weeks 2 and 3, erythema was higher for the PICC site than control (P<0.05). Although the sites did not differ for dryness at weeks 1 and 3, the PICC skin dryness was higher than control at week 2 (P<0.05). No differences in TEWL were observed, perhaps due to the limited sample size.
Discussion
We found that repetitive application of CHG and a semipermeable adhesive dressing (Tegaderm) to the PICC-site skin resulted in greater skin compromise, measured as erythema, dryness and barrier integrity (TEWL), relative to an adjacent untreated control. After 1 week of exposure to CHG þ dressing, PICC-site erythema and dryness scores were higher than the dressing site. Erythema for the dressing site was higher than the control. By week 3, erythema and dryness were comparable for the CHG þ dressing and dressing alone and both were higher than the untreated control. TEWL for CHG þ dressing was higher than the others at week 3, indicating greater SC compromise. We observed the starting erythema to be higher for lower GA infants. Pre-term SC has fewer layers permitting visualization of the capillaries and higher apparent erythema. 17 Application of 2% CHG in 70% isopropanol to the PICC site did not visibly increase erythema, suggesting the absence of an immediate inflammatory response. These findings indicate that the dressing may contribute to the observed PICC-site skin compromise after a period of prolonged exposure and repeated removal and reapplication of CHG and an adhesive semipermeable dressing.
Our results for the dressing site differed from some previous reports and were consistent with others. Tegaderm was applied one time to infants of 24 to 26 weeks GA and left in place for 2 to 3 weeks. On removal the skin had matured without irritation. 18 Semipermeable films (Opsite, Tegaderm) were placed on chest and abdomen for 2 to 4 h (25 to 36 weeks GA) and, following removal, TEWL was comparable to pre-application values. 19 TEWL for sites with dressings in place for 4 days were similar to untreated values, indicating no interference with barrier maturation. Infants p32 weeks GA were treated with a semipermeable dressing (Bioclusive) for 14 days and TEWL values were similar to those of an adjacent untreated site, suggesting normal SC maturation under the dressing. 20 Skin sites treated with a non-adhesive semipermeable dressing (Bioclusive) were compared with a contralateral untreated control in neonates <30 weeks GA. TEWL and bacterial counts were lower for the dressing site than the control on days 1, 2, 4 and 7, suggesting that the dressing facilitated SC barrier maturation. 21 The increased PICC-site TEWL that we observed might result from skin stripping with dressing changes. Our findings were consistent with Lund et al. 22 who examined the SC barrier disruption after single placement (24 h ) and removal of three adhesive tapes in younger infants (n ¼ 30, mean 30.3 weeks GA). TEWL and redness were higher for the plastic tape (Transpore, 3M, St Paul, MN, USA) and a pectin barrier (Hollihesive, Hollister, Libertyville, IL, USA) than a hydrophilic gel (CAS Medical Systems, Branford, CT, USA) and control. TEWL and the amount of protein removed increase with time, method and amount of applied pressure. 23 As PICC lines must remain accurately placed, the dressing application pressure may be greater for our subjects than in studies designed to determine dressing effects on skin integrity and stripping. When tapes were applied repeatedly to the same skin site (volar forearm), removal force and TEWL increased. 24 It is possible that our PICC dressings may be more difficult to remove over time. In an evaluation of commercially available tapes, some increased cumulative irritation and TEWL with repeated application over 14 days though others were comparable to untreated skin. 25 Some of the tapes were designed to provide moist wound healing (for example, Biatain, Comfeel Plus Transparent, Coloplast Corp, Minneapolis, MN, USA; DuoDERM ET, ConvaTec, Skillman, NJ, USA) and, therefore, the increased irritation and TEWL may be due to occlusion and tape stripping. Tapes of differing occlusivity were reapplied to the peri-wound leg skin. Some caused damage and others were similar to untreated skin. 26 The combination of CHG and dressing over time (between dressing changes) may behave as a film with relatively 'low water vapor permeability' to block water loss and allow water accumulation at the skin surface below the dressing. 27 The type of adhesive in the dressing may negatively affect permeability, that is, reduce the rate of moisture loss from the skin. 28 Occlusive films significantly delayed SC barrier repair following tape stripping relative to semipermeable dressings and no occlusion. 29 Increased SC hydration leads to maceration, lipid bilayer disruption, formation of amorphous intercellular regions and degradation of the corneodesmosomes. [30] [31] [32] Long-term occlusion of stripped skin caused loss of the epidermal Ca þ 2 gradient required for lipid synthesis, regulation of epidermal cell proliferation and differentiation to delay SC barrier recovery. [33] [34] [35] Hydrated skin has a higher frictional coefficient and may enhance the effects of mechanical trauma 36 . A study limitation is the small number infants <29 weeks (n ¼ 14 or 35% of the sample). We do not have sufficient information to comment on the effects of CHG on the skin of infants <29 weeks GA. Although the within-subject design reduces the required size, additional evaluations among a larger sample of this segment are needed, perhaps as a multi-site quality improvement initiative. We did not enroll every patient because of the required duration and medical stability and may have excluded the most vulnerable patients. Our study design did not include a weekly treatment of CHG alone (that is, CHG in isopropanol). We cannot separate the effects of the CHG and isopropanol from those of the CHG þ dressing combination to segregate the contribution of the antiseptic system to the observed outcomes. In addition, we assessed one CHG preparation thereby limiting generalization to all skin antiseptics. Further, it was not possible to blind the evaluators to the treatments, given the clinical design and NICU setting. Determination of CHG adsorption was beyond our scope, but remains a question, particularly for compromised skin. The issue arises in part from reports of neurotoxicity due to percutaneous absorption from wholebody exposure to hexachlorophene. CHG is a different compound and blood levels of 53 to 1021 ng ml À1 have been reported for premature infants after multiple exposures (cord care, bathing).
37,38 CHG amounts were <0.002 mg mg À1 in lower layers of full-thickness skin exposed for 24 h in vitro, indicating poor penetration, 39 but this does not replicate compromised skin exposed to CHG for 7 days. A more relevant model is the human skin substitute, which lacks a competent SC barrier. Application of 0.5% CHG in 70% alcohol for 24 h resulted in moderate cytotoxicity, comparable to zinc oxide cream and significantly less cytotoxic than Betadine (Purdue Products, LP, Stamford, CT, USA). 40 This study seems to be the first to examine the effects of dressing within the context of the CHG þ dressing treatment on PICC skin condition SC integrity among NICU patients. The findings highlight the contribution of tapes and dressings to the skin compromise observed in the clinical setting. Dressings with inherently higher water vapor permeability are expected to minimize the skin breakdown at PICC sites, but the adhesive characteristics and exposure conditions (for example, incubator temperature, humidity, and so on) need to be considered and evaluated. Investigation and/or development of alternatives that do not occlude the skin surface or strip the outer SC layers are important for insuring skin barrier integrity and creating conditions for barrier maturation in the neonatal population.
